Table 3.
Immune-related adverse event rates associated with ICIs in acute leukemia.
| Nivolumab (0.5–3 mg/kg) (Daver et al., 2019; Davids et al., 2018; Assi et al., 2018) |
Pembrolizumab (200 mg/m2) (Justin Kline et al., 2018; Lindblad et al., 2018; Zeidner et al., 2018) |
Ipilimumab (0.1–10 mg/kg) (Bashey et al., 2009; Davids et al., 2016) |
|
|---|---|---|---|
| ≥Grade 3 (%) | ≥Grade 3 (%) | ≥Grade 3 (%) | |
| Pneumonitis | 1 | 18 | 3.4–4.5 |
| Rash | 4.5 | 7.6 | |
| Pruritus | 3 | ||
| Transaminitis | 2–4 | 3.4 | |
| Colitis | 1–4.5 | 4.5 | |
| Pancreatitis | 2 | ||
| Elevated bilirubin | 4 | 10 | |
| Fatigue | 1 | ||
| Hepatitis | 7.6 | ||
| Hypotension | 10 | ||
| Diarrhea | 10 | ||
| Hyperthyroidism | 9–14 | ||
| Arthritis | 3.4 |